Skip to Content
Merck
  • Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.

Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.

Cancer research (2014-11-20)
Sara Gm Piccirillo, Inmaculada Spiteri, Andrea Sottoriva, Anestis Touloumis, Suzan Ber, Stephen J Price, Richard Heywood, Nicola-Jane Francis, Karen D Howarth, Vincent P Collins, Ashok R Venkitaraman, Christina Curtis, John C Marioni, Simon Tavaré, Colin Watts
ABSTRACT

Glioblastoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified fluorescent tissue in the sub-ependymal zone (SEZ) of patients with glioblastoma. Histologic analysis and genomic characterization revealed that the SEZ harbors malignant cells with tumor-initiating capacity, analogous to cells isolated from the fluorescent tumor mass (T). We observed resistance to supramaximal chemotherapy doses along with differential patterns of drug response between T and SEZ in the same tumor. Our results reveal novel insights into glioblastoma growth dynamics, with implications for understanding and limiting treatment resistance.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
cis-Diamineplatinum(II) dichloride, ≥99.9% trace metals basis
Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard
USP
Transplatin, United States Pharmacopeia (USP) Reference Standard
Supelco
Temozolomide, VETRANAL®, analytical standard
Sigma-Aldrich
Temozolomide, ≥98% (HPLC)
Sigma-Aldrich
trans-Platinum(II)diammine dichloride
Sigma-Aldrich
cis-Diammineplatinum(II) dichloride, crystalline
Cisplatin, European Pharmacopoeia (EP) Reference Standard
Supelco
Temozolomide, Pharmaceutical Secondary Standard; Certified Reference Material